Home » Our Services » Patient Engagement » Patient Preference Studies

Patient Preference Studies

Generate Patient Preference Evidence to Inform Development and Commercial Strategy

Patient experience can help biopharma and medtech companies make informed decisions across the product lifecycle and support engagement with regulators, HTA bodies, payers, and other stakeholders. Companies need approaches that systematically capture what matters to patients to realize this potential and generate robust, decision-grade evidence that meaningfully informs product development, access, and commercial strategy.

Patient preference studies provide critical structured insights into the relative importance patients assign to different characteristics when making decisions about treatment options.

Partner with Alira Health to design and conduct patient preference studies that quantify how patients value treatment benefits, risks, and trade-offs.

Patient Preference Studies as Decision-Grade Evidence

Patient preference studies provide a systematic, quantitative, and/or qualitative approach to understanding what patients value and the trade-offs they are willing to make.

Patient preference studies help:

Align product development and clinical trial design with patient priorities
Strengthen regulatory and HTA strategies with patient-centered evidence
Support benefit-risk assessments and value demonstration
Inform pricing, reimbursement, and market access strategies
Explain how preferences and trade-offs vary across patient populations and markets

Alira Health develops end-to-end patient preference studies designed to generate fit-for-purpose, decision-ready evidence, and maximize its impact across the product lifecycle.

Why Choose Alira Health for Patient Preference Studies?

The recent harmonized guideline ICH E22 about the use, design, conduct, analysis, and submission of patient preference studies clarifies how they can inform drug development, regulatory submission and evaluation, drug approvals, and maintenance of such approvals. Robust preference evidence generation requires understanding the strategic decision the evidence needs to support, engaging patients appropriately, applying rigorous analytical methods, and translating the findings into action.

Our integrated approach brings together three capabilities:

Strategic Patient Engagement and Consulting

We identify where and how patient preference evidence can add value across the product lifecycle, which ensures that each study features a clearly defined strategic objective and decision need.

Study Design and Methodology

We combine patient-informed qualitative and quantitative approaches, including discrete choice experiments and conjoint analysis, with advanced statistical expertise and patient engagement capabilities to generate rigorous, fit-for-purpose evidence.

Integration Across the Product Lifecycle

We help translate patient preference study findings into actionable evidence for regulatory and HTA submissions, value dossiers, clinical development decisions, and pre- and post-launch strategies.

Expert Insights

Article

Patient Preference Studies: Patient Experience as Decision-Grade Evidence

Discover how patient preference studies use qualitative and quantitative methods to generate decision-Grade Evidence across development and commercialization.

Read now